Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:DOMH

Dominari Q2 2024 Earnings Report

Dominari logo
$3.26 +0.10 (+3.16%)
Closing price 04:00 PM Eastern
Extended Trading
$3.28 +0.03 (+0.77%)
As of 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Dominari EPS Results

Actual EPS
-$0.51
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Dominari Revenue Results

Actual Revenue
$6.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dominari Announcement Details

Quarter
Q2 2024
Date
8/8/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Dominari's next earnings date is estimated for Tuesday, August 18, 2026, based on past reporting schedules.

Conference Call Resources

Dominari Earnings Headlines

Dominari Securities Raises $200,000,000.00 in World's Largest IPO
June 15 at 8:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/dominari-securities-raises-200-000-000-00-in-worlds-largest-ipo-302799798.html
Dominari (NASDAQ:DOMH) Trading Up 2.3% - What's Next?
June 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30827960
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
June 15 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Head to Head Contrast: Dominari (NASDAQ:DOMH) and Integrated BioPharma (OTCMKTS:INBP)
June 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30822718
Dominari Holdings Restructures Series B Warrants for Capital
May 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/dominari-holdings-restructures-series-b-warrants-for-capital?utm_source=marketbeat.com&utm_medium=referral
Dominari Holdings Congratulates Cerebras Systems on "Blockbuster" Initial Public Offering
May 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/dominari-holdings-congratulates-cerebras-systems-on-blockbuster-initial-public-offering-302773281.html
See More Dominari Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dominari? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dominari and other key companies, straight to your email.

About Dominari

Dominari (NASDAQ:DOMH), a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

View Dominari Profile
Earnings Tools